Johnson & Johnson Testing Experimental HIV Vaccine In U.S., Europe, Africa

CNBC: Johnson & Johnson to test HIV vaccine in U.S. and Europe
“Pharmaceutical giant Johnson & Johnson is set to test an experimental HIV vaccine in the U.S. and Europe sometime this year, the company confirmed with CNBC. The experimental J&J vaccine is a mosaic-based preventative immunization that targets various strains of the HIV virus. … The company is also conducting a phase 2 clinical trial for the vaccine in Africa, in which 2,600 women in five southern African countries will be immunized. Initial results from that trial are expected by 2021, J&J said…” (Lovelace/Turner, 7/12).

Additional coverage of the upcoming clinical trial is available from Bloomberg and Reuters.